Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

This trial is testing a two-step treatment approach for men with advanced prostate cancer that has stopped responding to hormone therapy (called metastatic castration-resistant prostate cancer, or mCRPC). First, patients receive a high dose of testosterone (which may briefly make cancer cells more vulnerable), followed by a radioligand therapy called PSMA-617 that delivers radiation directly to cancer cells. **You may be eligible if...** - You have advanced prostate cancer that has progressed despite hormone suppression therapy - Your cancer shows up on a PSMA PET scan (a special imaging test) - You have already received one type of hormone-blocking drug (ARPI) - You have mild or no cancer-related symptoms - You are in good general health (ECOG 0–1) - Your heart function is adequate **You may NOT be eligible if...** - Your cancer has spread to the spine covering (epidural), liver, or brain - You have had radiation therapy in the last 30 days - You have an active uncontrolled infection, heart problems, or other serious illness - You are currently on another experimental treatment Talk to your doctor to see if this trial is right for you.